Compare APEI & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APEI | MNKD |
|---|---|---|
| Founded | 1991 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 877.0M |
| IPO Year | 2007 | 2004 |
| Metric | APEI | MNKD |
|---|---|---|
| Price | $51.70 | $3.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $52.14 | $8.69 |
| AVG Volume (30 Days) | 230.8K | ★ 6.0M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.27 | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | $198,174,000.00 | ★ $348,966,000.00 |
| Revenue This Year | $8.47 | $35.81 |
| Revenue Next Year | $7.00 | $11.89 |
| P/E Ratio | $54.88 | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $25.81 | $2.23 |
| 52 Week High | $61.59 | $6.51 |
| Indicator | APEI | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 37.51 | 59.70 |
| Support Level | $50.04 | $2.45 |
| Resistance Level | $59.73 | $6.08 |
| Average True Range (ATR) | 2.48 | 0.26 |
| MACD | -0.50 | 0.01 |
| Stochastic Oscillator | 17.60 | 34.25 |
American Public Education Inc provides online and campus based postsecondary education including various undergraduate and graduate degree programs. The fields of study include business administration, health science, technology, criminal justice, education, liberal arts, national security, military studies, intelligence, and homeland security. There are three reporting segments: the American Public University segment which is the key revenue generator, provides online postsecondary education as a distance-learning, graduate-level institution for military officers seeking a degree in military studies; the Rasmussen University Segment and the Hondros College of Nursing segment. The revenue is generated from net course registrations and enrollment, tuition rate, net tuition, and other fees.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.